Bill Detail

H.R. 2450

Congress: 119

Title

Prescription Drug Transparency and Affordability Act

Summary

Prescription Drug Transparency and Affordability Act This bill requires pharmacy benefit managers (PBMs) to report, at least once every six months, prescription drug pricing, payment, and utilization data to the health insurance plans for which the PBM provides services. Specifically, a PBM contracted to provide services to an employer or sponsor offering a large group health insurance plan (i.e., a plan with at least 100 employees or participants) must report to the plan certain information for prescription drug claims under the plan. This includes, for each drug, the difference between the compensation paid by the plan to the PBM and the compensation paid by the PBM to the pharmacy. Further, for each therapeutic class of drugs under the plan, a PBM must report (1) the total amount it received in rebates, fees, and discounts; and (2) the net spending for each class after such rebates, fees, and discounts. Each PBM also must report certain information about (1) drugs for which total spending exceeded $10,000; and (2) drugs dispensed through pharmacies affiliated with the plan or PBM, such as the percentage of prescriptions dispensed by such affiliates. Finally, a PBM providing services to any group health insurance plan must provide the plan with a summary document that includes similar information for prescription drug claims under the plan, as determined by the Department of Health and Human Services. Plans must also make certain aggregate summary information available to plan participants. PBMs and plans that violate these requirements are subject to civil penalties.

Sponsor

Rep. Kristen McDonald Rivet [D-MI-8]

Status

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Status as of Nov 14, 2026, 1:15 PM · synced 1d ago

Introduced

2025-03-27

Data source mode: congress-gov

Bill Engagement

Lobbyists on the case

1 org · 12 lobbyists · 1 filing mention H.R. 2450 (Prescription Drug Transparency and Affordability Act) in LDA disclosures.

These are cached disclosure mentions, not verified current representation or confirmed event attendance.

Top orgs filing
Lobbyists on this bill
+ 10 more in the full intelligence view

Limited preview · paid intelligence

Keep the intelligence current—not just this one record.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.

SEE A FINISHED HEALTHCARE EXAMPLE

Three days of Hill visits. Two Medicare access questions.

A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.

Read the finished healthcare brief →
Buy Federal Intelligence · $2,500 for 3 monthsPrefer a walkthrough first?Already a customer? Sign inGet free intelligence alerts →

After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.